Wedbush reiterated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report published on Monday, TipRanks reports. They currently have a $37.00 price objective on the stock.
Several other research firms have also recently weighed in on AQST. HC Wainwright reiterated a buy rating and set a $14.00 price objective (up from $12.00) on shares of Aquestive Therapeutics in a research report on Monday. Zacks Investment Research upgraded Aquestive Therapeutics from a hold rating to a buy rating and set a $6.00 target price for the company in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $18.40.
Shares of NASDAQ:AQST opened at $8.74 on Monday. The firm has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $4.17. Aquestive Therapeutics has a 52 week low of $2.95 and a 52 week high of $10.00. The company has a market cap of $195.09 million, a PE ratio of -3.12 and a beta of 2.70.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Featured Article: Why are gap-down stocks important?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.